JP7397416B2 - 抗がん剤の分解方法 - Google Patents
抗がん剤の分解方法 Download PDFInfo
- Publication number
- JP7397416B2 JP7397416B2 JP2022521899A JP2022521899A JP7397416B2 JP 7397416 B2 JP7397416 B2 JP 7397416B2 JP 2022521899 A JP2022521899 A JP 2022521899A JP 2022521899 A JP2022521899 A JP 2022521899A JP 7397416 B2 JP7397416 B2 JP 7397416B2
- Authority
- JP
- Japan
- Prior art keywords
- anticancer drug
- anticancer
- ultraviolet
- decomposing
- ultraviolet light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims description 133
- 229940041181 antineoplastic drug Drugs 0.000 title claims description 102
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 37
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 32
- 229960004679 doxorubicin Drugs 0.000 claims description 31
- 230000001678 irradiating effect Effects 0.000 claims description 23
- 239000007789 gas Substances 0.000 claims description 19
- 229960004857 mitomycin Drugs 0.000 claims description 16
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 15
- 229960000684 cytarabine Drugs 0.000 claims description 15
- 229960005420 etoposide Drugs 0.000 claims description 13
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 13
- 229960004528 vincristine Drugs 0.000 claims description 12
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 12
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 12
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 10
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 10
- 229960002707 bendamustine Drugs 0.000 claims description 10
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 10
- 229960003901 dacarbazine Drugs 0.000 claims description 10
- 229960003668 docetaxel Drugs 0.000 claims description 10
- 229960004768 irinotecan Drugs 0.000 claims description 10
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 10
- 229960000485 methotrexate Drugs 0.000 claims description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 230000001699 photocatalysis Effects 0.000 claims description 4
- 239000004408 titanium dioxide Substances 0.000 claims description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
- 239000003790 pyrimidine antagonist Substances 0.000 claims description 3
- 229940123237 Taxane Drugs 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 239000004052 folic acid antagonist Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 150000004654 triazenes Chemical class 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 238000000862 absorption spectrum Methods 0.000 description 39
- 239000007864 aqueous solution Substances 0.000 description 28
- 239000000126 substance Substances 0.000 description 16
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 15
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 15
- 238000012795 verification Methods 0.000 description 10
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 6
- 229910052753 mercury Inorganic materials 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000000538 analytical sample Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- AQTQHPDCURKLKT-PNYVAJAMSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229960002110 vincristine sulfate Drugs 0.000 description 3
- 229910000838 Al alloy Inorganic materials 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 239000003972 antineoplastic antibiotic Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000011941 photocatalyst Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- 229910002601 GaN Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- RNQKDQAVIXDKAG-UHFFFAOYSA-N aluminum gallium Chemical compound [Al].[Ga] RNQKDQAVIXDKAG-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000004734 cutaneous carcinogenesis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- PNHVEGMHOXTHMW-UHFFFAOYSA-N magnesium;zinc;oxygen(2-) Chemical compound [O-2].[O-2].[Mg+2].[Zn+2] PNHVEGMHOXTHMW-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 239000005336 safety glass Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
- A62D3/10—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by subjecting to electric or wave energy or particle or ionizing radiation
- A62D3/17—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by subjecting to electric or wave energy or particle or ionizing radiation to electromagnetic radiation, e.g. emitted by a laser
- A62D3/176—Ultraviolet radiations, i.e. radiation having a wavelength of about 3nm to 400nm
Landscapes
- Physics & Mathematics (AREA)
- Electromagnetism (AREA)
- Optics & Photonics (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Business, Economics & Management (AREA)
- Emergency Management (AREA)
- Radiation-Therapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(手順)
ドキソルビシン塩酸塩(富士フィルム和光純薬社製、040-21521)に対して蒸留水を混合して、濃度200μg/mLのドキソルビシン水溶液X1を精製した。その後、25mm×20mm寸法のアルミホイル切片上に、ドキソルビシン水溶液を100μL滴下し、乾燥させることで、試験物Y1を作製した。
更に、複数種類の抗がん剤に対して、上記波長帯の紫外線L1を照射することで、分解できることにつき、別の方法で検証を行った。
検証対象となる抗がん剤としては、以下の物質が採用された。
・ナイトロジェンマスタード類:ベンダムスチン、マイトマイシンC
・ピリミジン拮抗薬:シタラビン
・アントラサイクリン系抗癌抗生物質:ドキソルビシン
・トポイソメラーゼ阻害薬:イリノテカン、エトポシド
・トリアゼン類:ダカルバジン
・ビンアルカロイド類:ビンクリスチン
・タキサン類:ドセタキセル
対象となる上記それぞれの抗がん剤に対して、所定の容器内で蒸留水を混合して水溶液を精製した。次に、それぞれの水溶液の、紫外線照射前における吸収スペクトルを吸光光度計(サーモフィッシャーサイエンス社製、NANODROP ONE)を用いて測定した。次に、それぞれの水溶液に対して照射面における照度2mW/cm2で、照射時間を変化させながら紫外線L1を照射し、照射後の吸収スペクトルを、上記と同様の方法で測定した。
以下、別実施形態について説明する。
2 :室内床
3 :作業台
4 :作業室
9 :HEPAフィルタ
10 :光源
11 :発光管
12G :発光ガス
13 :電極
13a :電極
13b :電極
20 :作業員
G1 :雰囲気
L1 :紫外線
Claims (6)
- 主ピーク波長が200nm以上、300nm未満の紫外線を、抗がん剤が付着した物体表面に照射する工程(a)を含むことを特徴とする、抗がん剤の分解方法。
- 前記工程(a)は、Kr及びClを含む発光ガスが封入されたエキシマランプから前記紫外線を照射する工程であることを特徴とする、請求項1に記載の抗がん剤の分解方法。
- 前記抗がん剤が、アントラサイクリン系抗癌抗生物質、葉酸拮抗薬、ナイトロジェンマスタード類、ピリミジン拮抗薬、トポイソメラーゼ阻害薬、トリアゼン類、ビンアルカロイド類、及びタキサン類からなる群に属する1種以上であることを特徴とする、請求項請求項1又は2に記載の抗がん剤の分解方法。
- 前記抗がん剤が、ドキソルビシンであることを特徴とする、請求項1又は2に記載の抗がん剤の分解方法。
- 前記抗がん剤が、メトトレキサート、シタラビン、ベンダムスチン、マイトマイシンC、シタラビン、イリノテカン、エトポシド、ダカルバジン、ビンクリスチン及びドセタキセルからなる群に属する1種以上であることを特徴とする、請求項1又は2に記載の抗がん剤の分解方法。
- 二酸化チタン粒子を含む光触媒水性組成物を前記物体表面に噴霧する工程を有しないことを特徴とする、請求項1~5のいずれか1項に記載の抗がん剤の分解方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020083193 | 2020-05-11 | ||
JP2020083193 | 2020-05-11 | ||
PCT/JP2021/017677 WO2021230192A1 (ja) | 2020-05-11 | 2021-05-10 | 抗がん剤の分解方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2021230192A1 JPWO2021230192A1 (ja) | 2021-11-18 |
JP7397416B2 true JP7397416B2 (ja) | 2023-12-13 |
Family
ID=78524381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022521899A Active JP7397416B2 (ja) | 2020-05-11 | 2021-05-10 | 抗がん剤の分解方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP7397416B2 (ja) |
WO (1) | WO2021230192A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003190975A (ja) | 2001-12-28 | 2003-07-08 | Japan Organo Co Ltd | 水中に含まれる薬理活性を有する化学物質の処理方法 |
US20100185037A1 (en) | 2009-01-21 | 2010-07-22 | Palo Alto Research Center Incorporated | Drug deactivation system and method of deactivating a drug using the same |
JP2012091114A (ja) | 2010-10-27 | 2012-05-17 | Iwate Medical Univ | 光触媒水性組成物及び該組成物を用いた抗がん剤分解法 |
JP2012525247A (ja) | 2009-04-30 | 2012-10-22 | ロワラ | 水中の生体異物を除去するための浄化方法および装置 |
WO2014208428A1 (ja) | 2013-06-25 | 2014-12-31 | 株式会社タムラテコ | 抗がん剤分解方法および抗がん剤分解装置 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08192175A (ja) * | 1995-01-17 | 1996-07-30 | Taiyo Kagaku Kogyo Kk | 有機物含有廃水の処理方法及びその装置 |
JP3822303B2 (ja) * | 1997-02-12 | 2006-09-20 | クォークシステムズ株式会社 | 有機化合物の分解方法および分解装置 |
-
2021
- 2021-05-10 WO PCT/JP2021/017677 patent/WO2021230192A1/ja active Application Filing
- 2021-05-10 JP JP2022521899A patent/JP7397416B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003190975A (ja) | 2001-12-28 | 2003-07-08 | Japan Organo Co Ltd | 水中に含まれる薬理活性を有する化学物質の処理方法 |
US20100185037A1 (en) | 2009-01-21 | 2010-07-22 | Palo Alto Research Center Incorporated | Drug deactivation system and method of deactivating a drug using the same |
JP2012525247A (ja) | 2009-04-30 | 2012-10-22 | ロワラ | 水中の生体異物を除去するための浄化方法および装置 |
JP2012091114A (ja) | 2010-10-27 | 2012-05-17 | Iwate Medical Univ | 光触媒水性組成物及び該組成物を用いた抗がん剤分解法 |
WO2014208428A1 (ja) | 2013-06-25 | 2014-12-31 | 株式会社タムラテコ | 抗がん剤分解方法および抗がん剤分解装置 |
Non-Patent Citations (1)
Title |
---|
臨床薬理,2001,Vol.32,No.1,p.15-22 |
Also Published As
Publication number | Publication date |
---|---|
WO2021230192A1 (ja) | 2021-11-18 |
JPWO2021230192A1 (ja) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11590359B2 (en) | Apparatus, method, and system for selectively effecting and/or killing bacteria | |
Metelmann et al. | Head and neck cancer treatment and physical plasma | |
Heinlin et al. | Plasma applications in medicine with a special focus on dermatology | |
Kojtari et al. | Chemistry for antimicrobial properties of water treated with non-equilibrium plasma | |
KR101069063B1 (ko) | 광선 치료기 | |
JP2022002749A (ja) | 気体処理装置 | |
CY1111726T1 (el) | Φαρμακευτικες συνθεσεις για τη θεραπεια του ασθματος | |
Choi et al. | Plasma bioscience for medicine, agriculture and hygiene applications | |
TW200510392A (en) | Chemical compounds | |
EP1393711B1 (en) | Photocatalytic bleaching agent for teeth and method | |
Sakai et al. | The amounts of hydroxyl radicals generated by titanium dioxide and 3.5% hydrogen peroxide under 405-nm diode laser irradiation | |
Ou et al. | Application of ultraviolet light sources for in vivo disinfection | |
JP7397416B2 (ja) | 抗がん剤の分解方法 | |
UY28366A1 (es) | Compuestos químicos | |
EP3950012A1 (en) | Method for inactivating bacteria or viruses and inactivating apparatus for bacteria or viruses | |
JP2024023265A (ja) | 静菌方法 | |
National Toxicology Program | Ultraviolet-radiation-related exposures | |
US20170354616A1 (en) | Onychomycosis treatment system and method | |
JP6505686B2 (ja) | 浸漬装置 | |
US10493263B2 (en) | Onychomycosis treatment system and method | |
US20180000937A1 (en) | Onychomycosis treatment system and method | |
JP7012065B2 (ja) | 即効性抗がん剤分解剤及び即効性抗がん剤分解方法 | |
WO2021205744A1 (ja) | ニコチンの分解方法 | |
EP4230229A1 (en) | Inactivation method and inactivation system | |
Boxhammer | Developmant of a safe therapeutic window for cold atmospheric plasma treatments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230825 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231101 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231114 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 7397416 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |